A Phase 1 interventional study of Ramucirumab and Necitumumab in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 1, and was the 10th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
SWOG Cancer Research Network · Sites in United States
Ages 18 min+
By country, each count listing its studies:
Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2009; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 24 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 127th largest by enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2016, is one of 28 in phase 1, and was the 117th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT03909334Xiuning LeStudy of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Are receiving chronic therapy with any of the following medications within 7 days prior to enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Finding: Participants received Ramucirumab 10 milligrams/kilogram (mg/kg) given intravenously (IV) on day 1 every 2 weeks and osimertinib 80 milligrams (mg) given orally daily during each 14-day cycle.
Drug: Ramucirumab · Drug: Osimertinib
Dose Finding: Participants received Necitumumab 800 mg given IV on days 1 and 8 every 3 weeks and osimertinib 80 mg given orally daily during each 21 day cycle.
Drug: Necitumumab · Drug: Osimertinib
Dose Expansion: Participants received Ramucirumab 10 mg/kg given IV on day 1 every 2 weeks and osimertinib 80 mg given orally daily during each 14-day cycle.
Drug: Ramucirumab · Drug: Osimertinib
Administered IV
Also known as: LY3009806
Administered IV
Also known as: LY3012211
Administered orally
Also known as: AZD9291
Phase 1a: Number of Participants With Dose Limiting Toxicities (DLTs)
A Dose Limiting Toxicity (DLT) was defined as one of the following Adverse Events (AE) that is likely related to the study drug or combination, and fulfils any one of the following criteria, graded according to the NCI-CTCAE Version 4.0: 1. Any nonhematologic Grade ≥3 toxicity, except for toxicities such as liver or renal function abnormality, skin rash that resolves with appropriate therapy, transient hypersensitivity and injection site reactions, myalgia, fatigue, constipation, electrolyte imbalance, nausea, vomiting, diarrhea 2. Hematologic toxicity was considered a DLT as the following: 1. Grade 4 toxicity lasting ≥7 days, or 2. Grade 3 or 4 thrombocytopenia if associated with bleeding or requires platelet transfusion, or 3. Febrile neutropenia 3. Death if considered related to study treatment 4. Any other significant toxicity deemed by the primary investigator and Lilly clinical research personnel to be dose limiting
Time frame: Arm A: Cycle 1 through Cycle 2 (14-day cycle); Arm B: Cycle 1 (21-day cycle)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
Cmin was the concentration of study drug in the blood immediately before the next dose was administered.
Time frame: Predose on Day (D) 1 of Cycle (C) 2, Predose on Day 1 of Cycle 4, Predose on Day 1 of Cycle 5, Predose on Day 1 of Cycle 7, Predose on Day 1 of Cycle 13
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab
Cmin was the concentration of study drug in the blood immediately before the next dose was administered.
Time frame: Predose on Day 1 of Cycle 3, Predose on Day 1 of Cycle 5
Objective Response Rate (ORR) for Ramucirumab in Combination With Osimertinib: Percentage of Participants With a Complete Response (CR) or Partial Response (PR)
ORR was the best overall response of complete response (CR) or partial response (PR) as classified by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). CR was a disappearance of all target and non-target lesions and normalization of tumor marker level. PR was an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.
Time frame: Baseline to Objective Disease Progression (up to 25 months)
Disease Control Rate (DCR) for Ramucirumab in Combination With Osimertinib: Percentage of Participants With CR, PR or Stable Disease (SD)
DCR was the best overall response of CR, PR, or SD as defined by RECIST v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or one or more new lesions.
Time frame: Baseline to Objective Disease Progression (up to 25 months)
Duration of Response (DoR) for Ramucirumab in Combination With Osimertinib
Duration of Response (DoR) was defined only for participants with a confirmed CR or PR. It was measured from the date of first evidence of a confirmed CR or PR to the date of objective progression or the date of death due to any cause, whichever is earlier. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date, DOR was censored at the date of the last complete objective progression-free disease assessment.
Time frame: Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (up to 25 months)
Progression Free Survival (PFS) for Ramucirumab in Combination With Osimertinib
Progression-free survival (PFS) was the time from the date of first study treatment until the date of radiographic documentation of progression (as defined by RECIST v. 1.1) based on investigator assessment or the date of death due to any cause, whichever was earlier. If a participant did not have a complete baseline disease assessment, then the PFS time was censored at the enrollment date, regardless of whether or not objectively determined disease progression or death was observed for the participant; otherwise, if a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last complete objective progression-free disease assessment date.
Time frame: Baseline to Measured Progressive Disease or Death from Any Cause (up to 26 months)
Overall Survival (OS) for Ramucirumab in Combination With Osimertinib
OS was date of first study treatment until death due to any cause. If the participant was alive at the data inclusion cutoff date for the analysis (or was lost to follow-up), OS was censored on the last date the participant was known to be alive.
Time frame: Baseline to Death from Any Cause (up to 29 months)
The study consisted of the dose-finding portion (Phase 1a) and the dose-expansion portion (Phase 1b) * Phase 1a, Arm A = combination of ramucirumab and osimertinib; Arm B = combination of necitumumab and osimertinib * Phase 1b included one cohort, the expansion of Arm A with additional participants enrolled i.e., Cohort A, a combination of ramucirumab and osimertinib. Per Protocol, all outcomes for a combination of ramucirumab and osimertinib were analyzed under a single arm i.e., Arm A/Cohort A
| Milestone | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib | Cohort A: Ramucirumab + Osimertinib |
|---|---|---|---|
| Started | 3 | 4 | 22 |
| Received at least one dose of study drug | 3 | 4 | 22 |
| Completed | 0 | 1 | 5 |
| Not completed | 3 | 3 | 17 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Physician decision | 2 | 0 | 1 |
| Withdrew: Progressive disease | 1 | 3 | 14 |
A Dose Limiting Toxicity (DLT) was defined as one of the following Adverse Events (AE) that is likely related to the study drug or combination, and fulfils any one of the following criteria, graded according to the NCI-CTCAE Version 4.0: 1. Any nonhematologic Grade ≥3 toxicity, except for toxicities such as liver or renal function abnormality, skin rash that resolves with appropriate therapy, transient hypersensitivity and injection site reactions, myalgia, fatigue, constipation, electrolyte imbalance, nausea, vomiting, diarrhea 2. Hematologic toxicity was considered a DLT as the following: 1. Grade 4 toxicity lasting ≥7 days, or 2. Grade 3 or 4 thrombocytopenia if associated with bleeding or requires platelet transfusion, or 3. Febrile neutropenia 3. Death if considered related to study treatment 4. Any other significant toxicity deemed by the primary investigator and Lilly clinical research personnel to be dose limiting
| Participants | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib |
|---|---|---|
| Phase 1a: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 |
Cmin was the concentration of study drug in the blood immediately before the next dose was administered.
| microgram per milliliter (µg/mL) | Arm A/Cohort A: Ramucirumab + Osimertinib |
|---|---|
| D1C2 | 41.3 ± 56.3 |
| D1C4 | 66.7 ± 34.3 |
| D1C5 | 76.7 ± 27 |
| D1C7 | 90.7 ± 26.6 |
| D1C13 | 103 ± 29.6 |
Cmin was the concentration of study drug in the blood immediately before the next dose was administered.
| nanograms per milliliter (ng/mL) | Arm B: Necitumumab + Osimertinib |
|---|---|
| D1C3 | NA ± NA |
| D1C5 | NA ± NA |
ORR was the best overall response of complete response (CR) or partial response (PR) as classified by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). CR was a disappearance of all target and non-target lesions and normalization of tumor marker level. PR was an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.
| Percentage of Participants | Arm A/Cohort A: Ramucirumab + Osimertinib |
|---|---|
| Objective Response Rate (ORR) for Ramucirumab in Combination With Osimertinib: Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | 76 (58.1 to 89.0) |
DCR was the best overall response of CR, PR, or SD as defined by RECIST v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or one or more new lesions.
| Percentage of Participants | Arm A/Cohort A: Ramucirumab + Osimertinib |
|---|---|
| Disease Control Rate (DCR) for Ramucirumab in Combination With Osimertinib: Percentage of Participants With CR, PR or Stable Disease (SD) | 92 (76.9 to 98.6) |
Duration of Response (DoR) was defined only for participants with a confirmed CR or PR. It was measured from the date of first evidence of a confirmed CR or PR to the date of objective progression or the date of death due to any cause, whichever is earlier. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date, DOR was censored at the date of the last complete objective progression-free disease assessment.
| Months | Arm A/Cohort A: Ramucirumab + Osimertinib |
|---|---|
| Duration of Response (DoR) for Ramucirumab in Combination With Osimertinib | 13.37 (9.63 to 21.19) |
Progression-free survival (PFS) was the time from the date of first study treatment until the date of radiographic documentation of progression (as defined by RECIST v. 1.1) based on investigator assessment or the date of death due to any cause, whichever was earlier. If a participant did not have a complete baseline disease assessment, then the PFS time was censored at the enrollment date, regardless of whether or not objectively determined disease progression or death was observed for the participant; otherwise, if a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last complete objective progression-free disease assessment date.
| Months | Arm A/Cohort A: Ramucirumab + Osimertinib |
|---|---|
| Progression Free Survival (PFS) for Ramucirumab in Combination With Osimertinib | 11.04 (5.49 to 19.29) |
OS was date of first study treatment until death due to any cause. If the participant was alive at the data inclusion cutoff date for the analysis (or was lost to follow-up), OS was censored on the last date the participant was known to be alive.
| Months | Arm A/Cohort A: Ramucirumab + Osimertinib |
|---|---|
| Overall Survival (OS) for Ramucirumab in Combination With Osimertinib | NA (16.03 to NA) |
Collected over Baseline to follow up (5.38 years). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Ramucirumab + Osimertinib | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Arm B: Necitumumab + Osimertinib | 1/4 (25%) | 1/4 (25%) | 4/4 (100%) |
| Cohort A: Ramucirumab + Osimertinib | 11/22 (50%) | 8/22 (36.4%) | 22/22 (100%) |
| Event | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib | Cohort A: Ramucirumab + Osimertinib |
|---|---|---|---|
| DiverticulitisInfections and infestations | 1/3 | 0/4 | 0/22 |
| Abdominal pain upperGastrointestinal disorders | 0/3 | 1/4 | 0/22 |
| PyrexiaGeneral disorders | 0/3 | 0/4 | 3/22 |
| PneumoniaInfections and infestations | 0/3 | 0/4 | 2/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 1/22 |
| Atrioventricular block second degreeCardiac disorders | 0/3 | 0/4 | 1/22 |
| Cardiac failure congestiveCardiac disorders | 0/3 | 0/4 | 1/22 |
| Intestinal obstructionGastrointestinal disorders | 0/3 | 0/4 | 1/22 |
| Pancreatitis acuteGastrointestinal disorders | 0/3 | 0/4 | 1/22 |
| Cystitis klebsiellaInfections and infestations | 0/3 | 0/4 | 1/22 |
| Event | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib | Cohort A: Ramucirumab + Osimertinib |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/3 | 4/4 | 14/22 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/3 | 0/4 | 6/22 |
| FatigueGeneral disorders | 0/3 | 3/4 | 3/22 |
| Dry skinSkin and subcutaneous tissue disorders | 1/3 | 3/4 | 2/22 |
| PyrexiaGeneral disorders | 2/3 | 1/4 | 3/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/3 | 1/4 | 4/22 |
| HypertensionVascular disorders | 1/3 | 0/4 | 14/22 |
| NauseaGastrointestinal disorders | 1/3 | 2/4 | 8/22 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 2/4 | 9/22 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 1/3 | 2/4 | 0/22 |
All enrolled participants
| Age, Categorical(Participants) | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib | Cohort A: Ramucirumab + Osimertinib | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 12 | 16 |
| >=65 years | 1 | 2 | 10 | 13 |
| Sex: Female, Male(Participants) | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib | Cohort A: Ramucirumab + Osimertinib | Total |
|---|---|---|---|---|
| Female | 1 | 3 | 17 | 21 |
| Male | 2 | 1 | 5 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib | Cohort A: Ramucirumab + Osimertinib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 4 | 22 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib | Cohort A: Ramucirumab + Osimertinib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 13 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 3 | 4 | 9 | 16 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Arm A: Ramucirumab + Osimertinib | Arm B: Necitumumab + Osimertinib | Cohort A: Ramucirumab + Osimertinib | Total |
|---|---|---|---|---|
| South Korea | 0 | 0 | 6 | 6 |
| United States | 1 | 1 | 3 | 5 |
| Taiwan | 0 | 0 | 5 | 5 |
| France | 0 | 1 | 0 | 1 |
| Spain | 2 | 2 | 8 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Oct 2017, 11 months.
Results were first posted in Feb 2024, 6 years 3 months after primary completion.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 11 months is below that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Necitumumab · Osimertinib
Carcinoma, Non-Small-Cell Lung →